Many Non-Hodgkin’s Lymphoma Patients Can Skip Radiation, Suggests Study Led by UArizona Researcher

Tuesday, December 10, 2019

A recent study led by a University of Arizona Cancer Center researcher suggests that many non-Hodgkin’s lymphoma patients can skip radiation in favor of a simpler course of treatment

Daniel Persky, MD, served as the lead investigator for the study administered by the SWOG Cancer Research Network (a clinical trials network funded by the National Cancer Institute). Results were presented Dec. 8 at the 61st American Society of Hematology (ASH) Annual Meeting in Orlando, Fla

The study found U.S. patients diagnosed with the most common subtype of non-Hodgkin’s lymphoma, diffuse large B-cell lymphoma (DLBCL), can safely skip radiation treatment after a clear positron emission tomography (PET) scan

Dr. Persky is associate director of clinical investigations and director, Clinical Trial Office – Tucson, at the UArizona Cancer Center. He specializes in hematology/oncology, particularly in lymphoid malignancies, such as lymphoma and CLL. In addition, he serves as an associate professor of medicine at the UArizona College of Medicine – Tucson

The SWOG Cancer Research Network announced the study results in the following news release: “No radiation needed for many aggressive non-Hodgkin's lymphoma patients.”

About the University of Arizona Cancer Center
The University of Arizona Cancer Center is the only National Cancer Institute-designated Comprehensive Cancer Center with headquarters in Arizona. The UArizona Cancer Center is supported by NCI Cancer Center Support Grant No. CA023074. With primary locations at the University of Arizona in Tucson and at Dignity Health St. Joseph’s Hospital and Medical Center in Phoenix, the Arizona Cancer Center has more than a dozen research and education offices throughout the state, with more than 300 physicians and scientists working together to prevent and cure cancer. For more information: (Follow us: Facebook | Twitter | YouTube

SWOG Cancer Research Network is part of the National Cancer Institute’s National Clinical Trials Network and the NCI Community Oncology Research Program, and is part of the oldest and largest publicly-funded cancer research network in the nation. SWOG has nearly 12,000 members in 47 states and six foreign countries who design and conduct clinical trials to improve the lives of people with cancer. SWOG trials have led to the approval of 14 cancer drugs, changed more than 100 standards of cancer care, and saved more than 3 million years of human life. Learn more at

Original Story Link: